Oxygen Biotherapeutics Hires Sales Director for Skin Care Products

Oxygen Biotherapeutics Hires Sales Director for Skin Care Products
DURHAM, N.C., May 18, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced it has hired Jim Weiss to the newly created position of Sales Director.  In this position, he will be responsible for coordinating and implementing the strategy to market and sell the Company's DermacyteTM line of oxygen-enriched skin care products to physician's offices, non-television direct marketing, and on the internet.  Effective May 24, he will report to Maria Isabel Tomargo, Assistant Vice President, Marketing and Sales.

Most recently, Weiss was a Marketing Practice Management consultant.  In this position, he established protocols and incentives to improve team work, profitability, revenue and new patient flow.  He also developed strategies to recruit, hire, train and evaluate the performance of a start-up sales team for a cardiovascular medical device company.  Previously, he was District Manager at NovaQuest Inc./ Eli Lilly responsible for hiring new field service personnel.  Earlier, he was District Business Manager for Novo Nordisk Inc. and was Northeast District Sales Manager at CollaGenex Pharmaceuticals Inc.  In these positions he managed sales personnel responsible for selling insulin, periodontal and dermatology products.

Weiss holds a bachelor's degree in Major Life Sciences with a minor in education from New York Institute of Technology.

"Jim's background in creating, developing and motivating start-up sales teams will be an essential component for us to move forward with our two-tier model to market and sell our Dermacyte products," said Chris Stern, chairman and CEO of Oxygen Biotherapeutics.

Dermacyte Oxygen Concentrate is now available for purchase online at www.buydermacyte.com and an eye cream and oxygen concentrate pumps should be available this summer.  These products will be marketed to physician's offices, spas, non-television direct marketing, and on the internet through a two-tier model:

Large urban areas will be targeted with our company sales force.
Large territories will be marketed through distributors and network marketing.
As a small biomedical company, Oxygen Biotherapeutics is well aware that it would be difficult to enter the extremely competitive retail market alone.  Consequently, the Company is seeking a partner that is able to explore the Dermacyte technology for products targeted at retail-based channels of trade, such as department stores, direct response television, in-flight and duty free shops, mass market retailers, and other food and drug retailers.  We will provide updates when any material agreements are secured.

About the Company

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body.  The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called OxycyteTM that is being formulated for both intravenous and topical delivery.  In April, the company launched its first cosmetic product, Dermacyte TM Oxygen Concentrate. In addition, the company is focused on perfluorocarbon-based oxygen carriers for use in traumatic brain injury, decompression sickness, personal care, and topical wound healing.  More information is available at www.oxybiomed.com.

The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release.  These statements include those referring to the plans for the expansion of the Dermacyte product line and the timing of the introduction of those new products.  Matters beyond the company's control could lead to delays in the new product introductions and customer acceptance of these new products.  Furthermore, there can be no assurance that such plans will lead to meaningful sales of Dermacyte or generate any revenue for the company.  The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.  This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company's securities.  No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation, or sale is unlawful.

CONTACT:  Oxygen Biotherapeutics, Inc.
          Ellen Corliss, Vice President, Corporate Communications
           & Investor Relations
          (919) 806-4405
 

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.